Moderate to Severe Crohn’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Moderate
to Severe Crohn’s Disease Market Outlook
Thelansis’s “Moderate to Severe
Crohn’s Disease Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2025 To 2035" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Moderate to Severe Crohn’s Disease
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Moderate
to Severe Crohn’s Disease Overview
Moderate to severe Crohn’s disease is a chronic, relapsing inflammatory bowel disorder that can affect any part of the gastrointestinal tract, most commonly the terminal ileum and colon. Patients experience persistent abdominal pain, diarrhea, weight loss, fatigue, and in advanced cases, complications such as strictures, fistulas, and abscesses. The disease is driven by dysregulated immune responses to intestinal microbiota in genetically susceptible individuals, leading to transmural inflammation and progressive tissue damage. Diagnosis is based on endoscopy, imaging, histopathology, and exclusion of other causes of intestinal inflammation. Management requires more intensive therapy than mild disease, often involving systemic corticosteroids, immunomodulators, and biologic agents targeting TNF‑α, integrins, or interleukins to control inflammation and prevent complications. Despite therapeutic advances, moderate to severe Crohn’s disease remains a major clinical challenge due to its unpredictable course, treatment resistance, and impact on quality of life, underscoring the need for personalized, multidisciplinary care.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment